Pioglitazone after Ischemic Stroke or Transient Ischemic Attack.
暂无分享,去创建一个
D. Tanné | K. Furie | C. Viscoli | W. Kernan | P. Peduzzi | R. Conwit | P. Guarino | H. Adams | S. Sen | L. Brass | J. Spence | A. Carolei | M. Parsons | G. Ford | L. Young | S. Inzucchi | P. Ringleb | M. Gorman | D. Kleindorfer | J. O’Leary | G. Schwartz | T. Winder | David Wang | B. Coull | W. Clark | L. Berger | A. Lovejoy | L. Young
[1] Wendy J Mack,et al. Pioglitazone Slows Progression of Atherosclerosis in Prediabetes Independent of Changes in Cardiovascular Risk Factors , 2013, Arteriosclerosis, thrombosis, and vascular biology.
[2] J. Panza,et al. Peroxisome Proliferator–Activated Receptor-γ Activation With Pioglitazone Improves Endothelium-Dependent Dilation in Nondiabetic Patients With Major Cardiovascular Risk Factors , 2006 .
[3] Reena Rao,et al. Thiazolidinediones expand body fluid volume through PPARγ stimulation of ENaC-mediated renal salt absorption , 2005, Nature Medicine.
[4] Andrew E Moran,et al. Global and regional burden of first-ever ischaemic and haemorrhagic stroke during 1990–2010: findings from the Global Burden of Disease Study 2010 , 2013, The Lancet. Global health.
[5] C. Peterson,et al. Expression of CD68 and macrophage chemoattractant protein-1 genes in human adipose and muscle tissues: association with cytokine expression, insulin resistance, and reduction by pioglitazone. , 2005, Diabetes.
[6] Yun-fa Jiang,et al. Risk of fracture with thiazolidinediones: an updated meta-analysis of randomized clinical trials. , 2014, Bone.
[7] J. Real,et al. Diagnosing insulin resistance by simple quantitative methods in subjects with normal glucose metabolism. , 2003, Diabetes care.
[8] Maarten L. Simoons,et al. The third universal definition of myocardial infarction , 2013 .
[9] Erland Erdmann,et al. Secondary prevention of macrovascular events in patients with type 2 diabetes in the PROactive Study (PROspective pioglitAzone Clinical Trial In macroVascular Events): a randomised controlled trial , 2005, The Lancet.
[10] V. Basevi. Standards of Medical Care in Diabetes—2010 , 2010, Diabetes Care.
[11] C. Viscoli,et al. Pioglitazone Improves Insulin Sensitivity Among Nondiabetic Patients With a Recent Transient Ischemic Attack or Ischemic Stroke , 2003, Stroke.
[12] C. Viscoli,et al. Insulin resistance and risk for stroke , 2002, Neurology.
[13] Mary G. George,et al. An Updated Definition of Stroke for the 21st Century: A Statement for Healthcare Professionals From the American Heart Association/American Stroke Association , 2013, Stroke.
[14] A. Baron,et al. Insulin resistance in the vasculature. , 2013, The Journal of clinical investigation.
[15] G. Shulman,et al. Efficacy and metabolic effects of metformin and troglitazone in type II diabetes mellitus. , 1998, The New England journal of medicine.
[16] R. Nesto,et al. Congestive heart failure and cardiovascular death in patients with prediabetes and type 2 diabetes given thiazolidinediones: a meta-analysis of randomised clinical trials , 2007, The Lancet.
[17] S. Aronoff,et al. Pioglitazone hydrochloride monotherapy improves glycemic control in the treatment of patients with type 2 diabetes: a 6-month randomized placebo-controlled dose-response study. The Pioglitazone 001 Study Group. , 2000, Diabetes care.
[18] C. Viscoli,et al. Impaired insulin sensitivity among nondiabetic patients with a recent TIA or ischemic stroke , 2003, Neurology.
[19] R. Turner,et al. Homeostasis model assessment: insulin resistance and β-cell function from fasting plasma glucose and insulin concentrations in man , 1985, Diabetologia.
[20] H. Chui,et al. The Modified Mini-Mental State (3MS) examination. , 1987, The Journal of clinical psychiatry.
[21] R. Rizza,et al. Comparison of the Effects of Pioglitazone and Metformin on Hepatic and Extra-Hepatic Insulin Action in People With Type 2 Diabetes , 2008, Diabetes.
[22] J. Hardies,et al. Effect of pioglitazone on abdominal fat distribution and insulin sensitivity in type 2 diabetic patients. , 2002, The Journal of clinical endocrinology and metabolism.
[23] E. Tuzcu,et al. Comparison of pioglitazone vs glimepiride on progression of coronary atherosclerosis in patients with type 2 diabetes: the PERISCOPE randomized controlled trial. , 2008, JAMA.
[24] F. Alla,et al. Pioglitazone and risk of bladder cancer among diabetic patients in France: a population-based cohort study , 2012, Diabetologia.
[25] D. Tanné,et al. Pioglitazone for secondary prevention after ischemic stroke and transient ischemic attack: rationale and design of the Insulin Resistance Intervention after Stroke Trial. , 2014, American heart journal.
[26] Ronac Mamtani,et al. Pioglitazone Use and Risk of Bladder Cancer and Other Common Cancers in Persons With Diabetes. , 2015, JAMA.
[27] 任艳,et al. 胰岛素增敏剂一Thiazolidinediones研究现状 , 2000 .
[28] R. Macko,et al. Treadmill Aerobic Training Improves Glucose Tolerance and Indices of Insulin Sensitivity in Disabled Stroke Survivors: A Preliminary Report , 2007, Stroke.
[29] V. Basevi. Diagnosis and Classification of Diabetes Mellitus , 2011, Diabetes Care.
[30] Jeffrey A. Johnson,et al. Thiazolidinedione use and cancer incidence in type 2 diabetes: a systematic review and meta-analysis. , 2012, Diabetes & metabolism.
[31] D. Betteridge,et al. Effects of Pioglitazone in Patients With Type 2 Diabetes With or Without Previous Stroke: Results From PROactive (PROspective pioglitAzone Clinical Trial In macroVascular Events 04) , 2007, Stroke.
[32] Hsien-Ho Lin,et al. Use of Thiazolidinediones and the Risk of Colorectal Cancer in Patients With Diabetes , 2013, Diabetes Care.
[33] Y. Hochberg. A sharper Bonferroni procedure for multiple tests of significance , 1988 .
[34] J. Carroll,et al. Letter by Saver et al regarding article, "Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association". , 2015, Stroke.
[35] C. Semenkovich,et al. Insulin resistance and atherosclerosis. , 2006, The Journal of clinical investigation.
[36] E. Kaplan,et al. Nonparametric Estimation from Incomplete Observations , 1958 .
[37] F. Verbrugge. Role of SGLT2 Inhibitors in Patients with Diabetes Mellitus and Heart Failure , 2017, Current Heart Failure Reports.
[38] K. Petersen,et al. Reversal of nonalcoholic hepatic steatosis, hepatic insulin resistance, and hyperglycemia by moderate weight reduction in patients with type 2 diabetes. , 2005, Diabetes.
[39] Alfonso T. Perez,et al. Effects of pioglitazone on bone in postmenopausal women with impaired fasting glucose or impaired glucose tolerance: a randomized, double-blind, placebo-controlled study. , 2013, The Journal of clinical endocrinology and metabolism.
[40] B. Balkau,et al. Comment on the provisional report from the WHO consultation , 1999, Diabetic medicine : a journal of the British Diabetic Association.
[41] J. Efird,et al. A Method to Compute Multiplicity Corrected Confidence Intervals for Odds Ratios and Other Relative Effect Estimates , 2008, International journal of environmental research and public health.
[42] A. Heyman,et al. Serial Changes in Glucose Utilization and Insulin and Growth Hormone Secretion in Acute Cerebrovascular Disease , 1972, Stroke.
[43] S. Haffner,et al. Effect of pioglitazone compared with glimepiride on carotid intima-media thickness in type 2 diabetes: a randomized trial. , 2006, JAMA.
[44] J. Broderick,et al. Incidence and Short-Term Prognosis of Transient Ischemic Attack in a Population-Based Study , 2005, Stroke.
[45] R. Haberl,et al. [Transient ischemic attack]. , 2009, MMW Fortschritte der Medizin.
[46] V. Raghavan. Insulin resistance and atherosclerosis. , 2012, Heart failure clinics.
[47] M. Laakso,et al. Relation of direct and surrogate measures of insulin resistance to cardiovascular risk factors in nondiabetic finnish offspring of type 2 diabetic individuals. , 2010, The Journal of clinical endocrinology and metabolism.
[48] R. Marfella,et al. Effect of a mediterranean-style diet on endothelial dysfunction and markers of vascular inflammation in the metabolic syndrome: a randomized trial. , 2004, JAMA.
[49] A. U. Rickel,et al. Guidelines for Prevention, I , 1998 .
[50] R. Sacco,et al. Recurrent stroke and cardiac risks after first ischemic stroke , 2006, Neurology.
[51] Maria Mori Brooks,et al. A randomized trial of therapies for type 2 diabetes and coronary artery disease. , 2009, The New England journal of medicine.
[52] I. Reid,et al. The skeletal effects of pioglitazone in type 2 diabetes or impaired glucose tolerance: a randomized controlled trial. , 2014, European journal of endocrinology.
[53] D.,et al. Regression Models and Life-Tables , 2022 .
[54] A. Hofman,et al. Pioglitazone and bladder cancer risk: a multipopulation pooled, cumulative exposure analysis , 2015, Diabetologia.